Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-03-28 | Aprea Therapeutics, Inc. | Hamill John P.
(SrVP/CFO/Prin Fin & Acct Ofcr) |
A | Common Stock | A | 3365 | $0.00 - $0.00 | $0 |
| 2024-03-28 | Aprea Therapeutics, Inc. | Gilad Oren
(President, CEO) |
A | Common Stock | A | 6725 | $0.00 - $0.00 | $0 |
| 2024-03-13 | Aprea Therapeutics, Inc. | Hamill John P.
(SrVP/CFO/Prin Fin & Acct Ofcr) |
P | Common Stock | A | 1010 | $7.29 - $7.29 | $7,362 |
| 2024-03-13 | Aprea Therapeutics, Inc. | Seizinger Bernd R.
(Director) |
P | Common Stock | A | 6860 | $7.29 - $7.29 | $50,009 |
| 2024-03-13 | Aprea Therapeutics, Inc. | HENNEMAN JOHN B III
(Director) |
P | Common Stock | A | 6860 | $7.29 - $7.29 | $50,009 |
| 2024-03-13 | Aprea Therapeutics, Inc. | Gilad Oren
(President, CEO) |
P | Common Stock | A | 2000 | $7.29 - $7.29 | $14,580 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |